Clinical trials: Medication Administration, open to volunteers
Neonatal Pain, Retinopathy of Prematurity (ROP)
Fentanyl Intranasal for Retinopathy of Prematurity Screening in Preterm Infants
The goal of this clinical trial is to learn whether intranasal fentanyl (a pain medicine given as a nasal spray) can reduce pain and is safe to use during routine eye examinations for retinopathy of prematurity (ROP) in preterm…
- Conditions
- Neonatal Pain, Retinopathy of Prematurity (ROP), Pain Management, Infant, Premature
- Trial name
- FIREFLY (NCT07112430)
- Testing
- Fentanyl Citrate (Intranasal)
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Marsha Campbell-Yeo
Breast Cancer
Real-world Studies of CDK4/6 Inhibitors
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment…
- Trial name
- NCT07407439
- Where
- China
- Volunteers
- 245 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Urinary Incontinence (UI)
Effectiveness of Chinese Herbal Medicine for Older Adults With Urinary Incontinence
This study aims to evaluate the effectiveness and safety of Chinese herbal medicine in improving urinary incontinence symptoms among older adults.
- Trial name
- NCT07637175
- Testing
- Chinese Herbal Medicine (CHM) supplement
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Kwantlen Polytechnic University
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Neuropathy, Cancer
Daily Hand-Held Vibration Therapy
The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands.
- Conditions
- Neuropathy, Cancer, Chemotherapeutic Drug - Induced Nephropathy, Chemotherapeutic Toxicity
- Trial name
- NCT04207437
- Testing
- Vibration therapy
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Indiana University
Advanced-stage Solid Tumors
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose…
- Trial name
- NCT07223125
- Testing
- JNJ-89862175
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 360 people
- Sponsor
- Janssen Research & Development, LLC
Stenosis of Native Hemodialysis Arteriovenous Fistulas
ACOART AVF RENEW: A Post Market Clinical Study
The objective of this prospective，multi-center，single arm study is to obtain further data on the safety and performance of the Acotec Orchid＆Dhalia Drug-coated Balloon catheters for the treatment of for the obstructive lesions in…
- Trial name
- NCT06205576
- Testing
- DCB catheter
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Acotec Scientific Co., Ltd
ECMO Treatment, ARDS
Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - "HemodynamECMOnitoring-VV Study"
In extracorporeal membrane oxygenation (ECMO), blood is drawn out of the body via tubes, oxygenated in an artificial lung; and then pumped back into the blood vessels.
- Conditions
- ECMO Treatment, ARDS, Pneumonia, Intensive Care
- Trial name
- NCT06593717
- Testing
- Transthoracic Echocardiography, Uncalibrated Pulse Contour Analysis, Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University of Vienna
Moyamoya Disease
Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
Moyamoya disease is a relatively rare chronic cerebrovascular disease, and its exact cause is currently unknown. This disease is characterized by the gradual narrowing or even blockage of important blood vessels in the brain (the…
- Trial name
- NCT07894640
- Testing
- Atorvastatin, Blood-cooling and Stasis-clearing Formula
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Muscle-Invasive Bladder Cancer (MIBC)
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin.
- Trial name
- NCT07647289
- Testing
- enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University Third Hospital
Oral Lichen Planus, Recurrent Aphthous Stomatitis
Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led Model
This study aims to improve how oral mucosal disorders-such as oral lichen planus, recurrent aphthous stomatitis, burning mouth syndrome, herpes viral infection and oral candidiasis-are treated in dental settings.
- Conditions
- Oral Lichen Planus, Recurrent Aphthous Stomatitis, Burning Mouth Syndrome, Oral Candidiasis
- Trial name
- NCT07721090
- Testing
- Pharmacist-Led Prescribing Optimization and Patient Counselling
- Volunteers
- 336 people
- Sponsor
- University of Fujairah
Infections, Bacterial, Pharmacokinetics
Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
The primary aim of the study is to determine the proportion of individuals receiving beta-lactam antibiotics at Imperial College Healthcare NHS Trust in whom drug concentration targets are achieved.
- Conditions
- Infections, Bacterial, Pharmacokinetics, Drug Monitoring, Drug-Related Side Effects and Adverse Reactions
- Trial name
- DATATDM (NCT06427317)
- Where
- United Kingdom
- Volunteers
- 323 people
- Sponsor
- Imperial College London
GERD (Gastroesophageal Reflux Disease)
Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of Smartphone Application GERDCare
Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors.
- Trial name
- AppGERD (NCT07127276)
- Testing
- Mobile application GERDCare
- Where
- Vietnam
- Volunteers
- 380 people
- Sponsor
- Institute of Gastroenterology and Hepatology, Vietnam
Melanoma
Perioperative Treatment With Tranexamic Acid in Melanoma
Surgery is a key element in the treatment of melanoma, and naturally linked with an inflammatory response and recruitment of innate immune cells.
- Trial name
- PRIME (NCT05899465)
- Testing
- Tranexamic acid, Saline
- Where
- 5 sites in Denmark
- Volunteers
- 1,204 people
- Sponsor
- University of Aarhus
Cardio-vascular Disease, Depression Disorders
Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland
In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland.
- Conditions
- Cardio-vascular Disease, Depression Disorders, Diabetes, COPD
- Trial name
- myCare Start-I (NCT07036471)
- Testing
- myCare Start
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- University of Geneva, Switzerland
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Femoropopliteal In-Stent Restenosis (ISR)
Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis
Femoropopliteal in-stent restenosis (ISR) remains an important cause of recurrent symptoms and repeat revascularization after lower-extremity endovascular treatment.
- Trial name
- NCT07277218
- Testing
- Drug-Coated Balloon-First Strategy, Eluvia Drug-Eluting Stent-First Strategy
- Where
- 10 sites in China
- Volunteers
- 600 people
- Sponsor
- Chunshui He
Pelvic Venous Disorders
Venoactive Drug Treatment of Pelvic Venous Disorders
Venoactive drug (VAD) therapy is one of the most effective methods of treating chronic venous diseases (CVD). Numerous studies have proven its high efficacy in relieving symptoms of CVD, such as leg pain and swelling, leg…
- Trial name
- VENOTREAT (NCT06584799)
- Testing
- Micronized purified flavonoid fraction, Diosmin 600, Hesperidin+Diosmin combination 1000
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Pirogov Russian National Research Medical University
Cancer Metastatic
Improving Public Cancer Care by Implementing Precision Medicine in Norway
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as…
- Trial name
- IMPRESS-N (NCT04817956)
- Testing
- Atezolizumab
- Where
- 17 sites in Norway
- Volunteers
- 3,000 people
- Sponsor
- Oslo University Hospital
Advanced or Metastatic Urothelium Cancer
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or…
- Trial name
- NCT05754853
- Testing
- MRG002, Docetaxel Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Shanghai Miracogen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.